Session Type
Meeting
Search Results for Antibiotic
Abstract Number: 261
Hospital Medicine 2019, March 24-27, National Harbor, Md.
Background: Growing antimicrobial resistance, C. difficile infection and cost have triggered a greater reliance on antimicrobial stewardship. Most stewardship models rely upon a central team, often led by ID specialists, to oversee prescribing in an institution. However, there are limitations to this paradigm. Purpose: We believe opportunities exist for hospitalists to drive stewardship by integrating […]
Abstract Number: 261
SHM Converge 2023
Background: Community acquired pneumonia (CAP) is one of the most common causes of hospitalization in the United States1 and a frequent source of antibiotic overuse.2 Two thirds of patients hospitalized for CAP receive excess antibiotic duration, primarily from excess therapy at discharge.3 Patients living in rural areas are known to have worse health outcomes than […]
Abstract Number: 271
Hospital Medicine 2018; April 8-11; Orlando, Fla.
Background: Uncomplicated Urinary Tract Infections (UTIs) account for more than 100,000 inpatient admissions yearly. IDSA guidelines recommend Nitrofurantoin as first line therapy and recent FDA guidelines recommend against Fluoroquinolone (FQ) use due their side effects and growing resistance; however, Sulfamethoxazole/Trimethoprim (Bactrim) and Ciprofloxacin are still commonly used to treat uncomplicated UTIs. Therefore we hypothesized that […]
Abstract Number: 275
Hospital Medicine 2017, May 1-4, 2017; Las Vegas, Nev.
Background: Approximately 1-2% of the U.S. population gets community-acquired pneumonia (CAP) annually in the U.S. and CAP is associated with substantial mortality, morbidity and costs. While the incidence of CAP is well-defined, the incidence of outpatients who fail antibiotics and eventually become hospitalized is less clear. The objective of this study was to provide real-world […]
Abstract Number: 281
Hospital Medicine 2017, May 1-4, 2017; Las Vegas, Nev.
Background: Inappropriate antibiotic use is associated with bacterial resistance, adverse events, and an increased risk of Clostridium difficileinfection. However, providers often prescribe antibiotics for viral respiratory infections and treat infections such as bacterial pneumonia for unnecessarily prolonged durations. Serum procalcitonin (PCT)-guided treatment is known to safely reduce antibiotic use and duration of treatment in pneumonia. […]
Abstract Number: 285
SHM Converge 2023
Background: Asymptomatic bacteriuria (ASB), the presence of bacteria in urine without signs or symptoms of a urinary tract infection, is a common finding. The current recommendation by the Infectious Diseases Society of America is against screening for and treating ASB in patients undergoing non-urologic surgeries, due to the lack of demonstrable benefit in reducing the […]
Abstract Number: 331
Hospital Medicine 2018; April 8-11; Orlando, Fla.
Background: Rifaximin, a nonsystemic antibiotic, may be used alone or in combination with lactulose for reducing the risk of overt hepatic encephalopathy (OHE) recurrence in adults. This analysis evaluated rifaximin alone and rifaximin + lactulose (combination) on health-related quality of life (QOL) and caregiver burden in patients with a history of OHE. Methods: In a […]
Abstract Number: 356
SHM Converge 2023
Background: The CDC recognizes antimicrobial resistance as an urgent global public health threat and supports antibiotic stewardship initiatives to combat antibiotic resistance. Pneumonia is a frequent condition treated by both hospitalists and emergency room physicians and the most common reason for inpatient antibiotic use and over prescribing. Recent IDSA guidelines for the treatment of community […]
Abstract Number: 359
Hospital Medicine 2018; April 8-11; Orlando, Fla.
Background: Hepatic encephalopathy (HE) is a common neurological complication in patients with cirrhosis. In addition to numerous morbidity-related issues, HE is associated with substantial economic burden. Treatment includes lactulose or rifaximin, a nonsystemic antibiotic that is indicated for reducing the risk of overt HE recurrence in adults. Rifaximin has also been shown to reduce the […]
Abstract Number: 403
SHM Converge 2024
Background: People who inject drugs (PWID) are at high-risk for developing serious injection related infections requiring long-term IV antibiotic therapy. For infective endocarditis, current guidelines recommend at least 4 to 6 weeks of IV antibiotic therapy. In PWID, it is recommended this be completed in a supervised setting because discharge home with a PICC line […]